These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24964698)

  • 41. A comparison of methods for converting DCE values onto the full health-dead QALY scale.
    Rowen D; Brazier J; Van Hout B
    Med Decis Making; 2015 Apr; 35(3):328-40. PubMed ID: 25398621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation.
    Ruchlin HS; Insinga RP
    Pharmacoeconomics; 2008; 26(11):925-35. PubMed ID: 18850762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What value health?: A review of health state values used in early technology assessments for NICE.
    Stein K; Fry A; Round A; Milne R; Brazier J
    Appl Health Econ Health Policy; 2005; 4(4):219-28. PubMed ID: 16466273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement.
    Hong J; Bae EY
    Pharmacoeconomics; 2021 Oct; 39(10):1109-1121. PubMed ID: 34318442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sensitivity analysis for handling uncertainty in an economic evaluation.
    Limwattananon S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S59-64. PubMed ID: 24964700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A systematic review of health state utility values in Thai cancer patients.
    Kangwanrattanakul K
    Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1171-1186. PubMed ID: 36084926
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The role of utilities in economic evaluations of healthcare interventions-an introduction].
    Maetzel A
    Z Rheumatol; 2004 Oct; 63(5):380-4. PubMed ID: 15517298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010.
    Wisløff T; Hagen G; Hamidi V; Movik E; Klemp M; Olsen JA
    Pharmacoeconomics; 2014 Apr; 32(4):367-75. PubMed ID: 24477679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A framework for estimating health state utility values within a discrete choice experiment: modeling risky choices.
    Robinson A; Spencer A; Moffatt P
    Med Decis Making; 2015 Apr; 35(3):341-50. PubMed ID: 25349189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population preferences of undergoing brachioplasty for arm laxity.
    Ibrahim AM; Sinno HH; Izadpanah A; Vorstenbosch J; Dionisopoulos T; Lee BT; Lin SJ
    Ann Plast Surg; 2014 Dec; 73 Suppl 2():S149-52. PubMed ID: 25046669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Neuropharmacoeconomics].
    Chiu HC
    Acta Neurol Taiwan; 2004 Jun; 13(2):87-96. PubMed ID: 15478681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review of health utilities across conditions common in paediatric and adult populations.
    Tarride JE; Burke N; Bischof M; Hopkins RB; Goeree L; Campbell K; Xie F; O'Reilly D; Goeree R
    Health Qual Life Outcomes; 2010 Jan; 8():12. PubMed ID: 20105304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estimating health state utility values from discrete choice experiments--a QALY space model approach.
    Gu Y; Norman R; Viney R
    Health Econ; 2014 Sep; 23(9):1098-114. PubMed ID: 24943827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Guidelines for health technology assessment in Thailand (second edition)--the development process.
    Chaikledkaew U; Kittrongsiri K
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S4-9. PubMed ID: 24964693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Using QALYs in telehealth evaluations: a systematic review of methodology and transparency.
    Bergmo TS
    BMC Health Serv Res; 2014 Aug; 14():332. PubMed ID: 25086443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Impact of Different DCE-Based Approaches When Anchoring Utility Scores.
    Norman R; Mulhern B; Viney R
    Pharmacoeconomics; 2016 Aug; 34(8):805-14. PubMed ID: 27034244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quality-adjusted life years, utility theory, and healthy-years equivalents.
    Mehrez A; Gafni A
    Med Decis Making; 1989; 9(2):142-9. PubMed ID: 2501627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Health state valuation methods and reference points: the case of tinnitus.
    Happich M; Moock J; von Lengerke T
    Value Health; 2009; 12(1):88-95. PubMed ID: 19911443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments.
    Longworth L; Rowen D
    Value Health; 2013; 16(1):202-10. PubMed ID: 23337232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incorporating process utility into quality adjusted life years: a systematic review of empirical studies.
    Brennan VK; Dixon S
    Pharmacoeconomics; 2013 Aug; 31(8):677-91. PubMed ID: 23771494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.